The CBY1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa cervical adenocarcinoma cell line, with targeted disruption of the CBY1 gene. This heterogeneous pool of engineered cells enables loss-of-function studies in a widely used cancer model. The polyclonal format minimizes clonal artifacts and maintains population-level gene inactivation, providing a robust tool for investigating CBY1-dependent biology. As a CRISPR/Cas9-edited product, it preserves endogenous regulatory contexts and is suited for functional genomics, pathway analysis, and drug discovery. The cells are provided as a ready-to-use format with verified gene disruption for reproducible downstream applications.
HeLa cells are a human cervical adenocarcinoma line, HPV18-positive and tumor-derived, extensively characterized in cancer research. They exhibit integrated HPV18 DNA, leading to E6 and E7 oncoprotein expression that inactivates p53 and RB, providing a permissive background for oncogenic signaling studies. The cells endogenously express canonical Wnt pathway components??including frizzled receptors, dishevelled, GSK3B, APC, AXIN, and CTNNB1??making them an ideal context for interrogating Wnt/beta-catenin regulation. Their robust growth, adherent morphology, and ease of genetic manipulation support the generation of knockout models for dissecting gene function in cancer-relevant settings.
CBY1 is a negative regulator of Wnt/beta-catenin signaling. It binds the C-terminal region of CTNNB1, preventing its binding to TCF7L2 and LEF1, thereby inhibiting transcription of Wnt targets such as MYC, CCND1, and AXIN2. YWHAZ (14-3-3 zeta) modulates CBY1-CTNNB1 interaction. In the absence of WNT3A, the destruction complex (GSK3B, APC, AXIN) phosphorylates CTNNB1 for degradation; CBY1 reinforces this repression. Furthermore, CBY1 localizes to ciliary basal bodies via CEP164 interaction, playing a role in ciliogenesis and connecting Wnt signaling to ciliary function.
In HeLa cells, disruption of CBY1 removes a key inhibitory constraint on beta-catenin/TCF transcriptional activity, potentially leading to Wnt pathway hyperactivation. Given the HPV18-positive background with E6 and E7 oncoproteins that may stabilize beta-catenin, CBY1 knockout may synergistically enhance oncogenic Wnt signaling, making it a powerful model for studying beta-catenin-driven tumorigenesis, epithelial-mesenchymal transition, and cancer cell proliferation. Additionally, the presence of primary cilia in HeLa cells under certain conditions allows investigation of CBY1’s role in ciliogenesis, providing insights into cancer-related ciliary dysfunction. The polyclonal nature avoids clonal artifacts, ensuring observed phenotypes reflect population-level gene disruption relevant to disease biology.
The CBY1 Knockout HeLa Polyclonal Cells support diverse applications, including Wnt/beta-catenin signaling studies using TOP/FOPFlash luciferase reporter assays to measure TCF/LEF transcriptional activity, and RT-qPCR quantification of Wnt target genes (e.g., MYC, CCND1, AXIN2). Co-immunoprecipitation of endogenous CBY1 with CTNNB1 or YWHAZ enables protein-protein interaction analysis, while western blotting assesses total and active beta-catenin. Immunofluorescence microscopy can visualize ciliary localization defects. High-throughput screening assays for Wnt inhibitors and cell proliferation/viability assays are readily performed. For further information, please contact Ascent Research.
